RXRX
Recursion Pharmaceuticals-A
NASDAQ · Biotechnology
$3.98
+0.42 (+11.80%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 111.69M | 62.24M | 351.21M | 309.68M | 294.04M |
| Net Income | -880,041,098 | -441,344,582 | -18,064,955 | -18,426,824 | -18,068,813 |
| EPS | — | — | — | — | — |
| Profit Margin | -788.0% | -748.6% | -5.1% | -6.0% | -6.2% |
| Rev Growth | +79.5% | +79.5% | -2.2% | +0.8% | +16.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 26.74M | 26.74M | 746.24M | 749.18M | 743.53M |
| Total Equity | 1.01B | 1.01B | 1.65B | 1.60B | 1.68B |
| D/E Ratio | 0.03 | 0.03 | 0.45 | 0.47 | 0.44 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -873,431,291 | -462,364,719 | -22,133,294 | -21,116,374 | -17,901,910 |
| Free Cash Flow | — | — | -14,520,850 | -13,211,156 | -10,972,266 |